Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia Clinical Trial

Official title:

Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01699152
• Other study ID #: TG02-102
• Status: Completed
• Phase: Phase 1
• Start date: September 2012
• Est. completion date: May 2016

Study information

• Verified date: May 2016
• Source: Tragara Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, open-label, dose escalation study.

Description:

The primary objective is to determine the highest dose of TG02 citrate that can be safely given to patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: May 2016
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have histologically confirmed Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma.

• Patients must meet one or more of the following indications for treatment:

1. Progressive disease or marked splenomegaly and/or lymphadenopathy.

2. Anemia (hemoglobin <11 mg/dL) or thrombocytopenia (platelets<100,000/µL).

3. Unexplained weight loss exceeding 10% of body weight over the previous 6 months.

4. CTCAE Grade 2 or 3 fatigue.

5. Fevers >100.5º F or night sweats for more than 2 weeks without evidence of infection.

6. Progressive lymphocytosis, with an increase exceeding 50% over a 2 month period or a doubling time of less than 6 months.

7. Need for cytoreduction prior to allogeneic stem cell transplant.

• Patients must have relapsed or refractory disease after =1 prior line of treatment.

• The interval from prior treatment to time of study drug administration should be at least 5 half-lives for cytotoxic and noncytotoxic agents.

• Low-dose corticosteroids (prednisone <20 mg/ day or equivalent dose) are permitted throughout study.

• Clinically significant toxicities from prior chemotherapy must be resolved to Grade = 1.

• Age >18 years.

• ECOG performance status =2.

• Life expectancy = 12 weeks.

• Patients must have normal organ and marrow function as defined below:

• absolute neutrophil count >1,000/µL in absence of bone marrow involvement

• platelets =30,000/µL in absence of bone marrow involvement

• If patient has extensive bone marrow involvement, minimum ANC and platelet levels are not required.

• total bilirubin =1.5 X institutional ULN unless due to Gilbert's syndrome, controlled autoimmune hemolytic anemia or immune thrombocytopenia

• AST(SGOT)/ALT(SGPT) <2.5 X institutional ULN unless due to disease

• creatinine <2.0 mg/dL OR creatinine clearance >50 mL/min/1.73 m2

• Negative serum or urine pregnancy test at the time of first dose for WOCBP.

• Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for required assessments.

• Ability to take oral medication.

Exclusion Criteria:

• Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (CTCAE Grade > 1) due to agents administered more than 3 weeks earlier.

• Patients who have received prior treatment with a CDK inhibitor within 12 months of study enrollment.

• High-dose corticosteroids (prednisone =20mg/day or equivalent dose) must be discontinued = 7 days of initiating therapy.

• Patients with known central nervous system involvement.

• History of allergic reactions attributed to compounds of similar chemical or biologic composition as TG02 citrate.

• Patients with G6PD deficiency.

• Concurrent severe or uncontrolled medical disease (including but not limited to history of ventricular arrhythmia or symptomatic conduction abnormality within 12 months, ongoing or active systemic infection, diabetes, hypertension, coronary artery disease, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations) that, in the opinion of the Investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study.

• Pregnant and/or breast-feeding women.

• Prior or second malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical or breast cancer, or other cancer for which the subject has received curative therapy at least 3 years prior to study entry.

• Known HIV or AIDs.

• QTc interval prolongation >450ms for males and >470 ms for females.

Related Conditions & MeSH terms

• Chronic Lymphocytic Leukemia
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Lymphoma
• Small Lymphocytic Lymphoma

Intervention

Drug:
• TG02 citrate
TG02 citrate capsules

Locations

Country	Name	City	State
United States	GRU	Augusta	Georgia
United States	DFCI	Boston	Massachusetts
United States	OSU	Columbus	Ohio
United States	MDACC	Houston	Texas
United States	SCRI	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Tragara Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose	To assess the number of patients with dose-limiting toxicities (DLT) and the dose of TG02 citrate that can be safely given to patients with CLL or SLL.	28 days
Secondary	Adverse Events	The number of patients with adverse events	28 days